



PROGRAM

APRIL 26, 2025

SATELLITE SYMPOSIUMS OF COMPANIES, SATELLITE REPORTS OF COMPANIES	
Hall 1	
CHAIRMEN Dr. Elena Parovichnikova, MD, Moscow, Russia Dr. Sergey Bondarenko, MD, St. Petersburg, Russia	
10.00-10.15	Targeted therapy for refractory and relapsed AML-basic option to achieve remission before performing HSCT Dr. Irina Lukyanova, MD, Moscow, Russia <i>with the support of the Astellas</i>
10.15-10.20	Questions
10.20-10.35	The advantages of TKI maintenance therapy (lafter ao-HSCT Dr. Sergey Bondarenko, MD, St. Petersburg, Russia <i>with the support of the Astellas</i>
10.35-10.40	Questions
10.40-11.00	Treatment of newly diagnosed acute myeloid leukemia: can we do better? Dr. Larisa Girshova, MD, St. Petersburg, Russia <i>with the support of Pfizer</i>
11.00-11.05	Questions
11.05-11.20	CAR-T therapy: evolving art of ALL treatment Dr. Olga Aleshina, MD, Moscow, Russia <i>with the support of Novartis</i>
11.20-11.25	Questions
11.25-11.35	Discussion
Hall 2	
CHAIRMEN Dr. Evgeny Zvonkov, MD, Moscow, Russia Prof. Dr. Evgeny Nikitin, MD Moscow, Russia	
10.00-10.20	Mosunetuzumab: how to improve treatment results of relapsed follicular lymphoma? Dr. Ekaterina Gitelzon MD, Moscow, Russia <i>with the support of the JSC «Roche-Moscow»</i>
10.20-10.25	Questions
10.25-10.45	Glofitamab in the treatment of relapsed/refractory DLBCL: from theory to practice Dr. Evgeny Zvonkov, MD, Moscow, Russia <i>with the support of the JSC «Roche-Moscow»</i>
10.45-10.50	Questions
NANOLEK SATELLITE SYMPOSIUM	
MODERATOR Prof. Dr. Evgeny Nikitin, MD, Moscow, Russia	
10.50-11.10	Current CLL 1st line treatment options, depending on risk factors Dr. Inga Piskunova, MD, Moscow, Russia <i>with the support of the Nanolek</i>
11.10-11.15	Questions
11.15-11.35	Analysis of treatment tactics in R/R CLL Dr. Maria Kislova, MD, Moscow, Russia <i>with the support of the Nanolek</i>
11.35-11.40	Questions
11.40-11.55	Real world evidence in CLL treatment: last decade and future overview Prof. Dr. Evgeny Nikitin, MD, Moscow, Russia <i>with the support of LLS «Johnson&Johnson»</i>
11.55-12.00	Questions
	Discussion
Hall 1	
CHAIRMEN Dr. Anahit Melikyan, MD, Moscow Russia Prof. Dr. Anna Turkina, MD, Moscow, Russia Dr. Nadezhda Zozulya, MD, Moscow, Russia	
12.00-12.15	Results of asciminib treatment in CML patients with the T3151 mutation in the MAP program Dr. Anna Petrova, MD, Moscow, Russia <i>with the support of the Novartis</i>
12.15-12.20	Questions
12.20-13.00	Chronic GVHD: modern approaches to treatment in the Russian Federation Dr. Mikhail Drovkov, MD, Moscow, Russia Prof. Dr. Ivan Moiseev, MD, St. Petersburg, Russia <i>with the support of the JSC «Sanofi Russia»</i>
13.00-13.15	Experience in the diagnosis and treatment of systemic mastocytosis at the NMRC for Hematology the Ministry of Health of the Russian Federation Dr. Anahit Melikyan, MD, Moscow, Russia <i>with the support of the Novartis</i>
13.15-13.20	Questions
13.20-13.40	General surgery in the era of emicizumab: Russian experience and key conclusions Dr. Sergey Shutov, MD, Moscow, Russia <i>with the support of the JSC «Roche-Moscow»</i>
13.40-13.45	Questions
13.45-14.05	The practice of orthopedic surgery in patients receiving emicizumab Dr. Tatyana Polyanskaya, MD, Moscow, Russia <i>with the support of the JSC «Roche-Moscow»</i>
14.05-14.10	Questions
14.10-14.30	Modern aspects of hemophilia A treatment Dr. Nadezhda Zozulya, MD, Moscow, Russia <i>with the support of the Sobi</i>
14.30-14.35	Questions
14.35-14.55	Systemic mastocytosis. Unresolved problems in diagnosis and treatment Dr. Dzharriyat Shikhbabayeva, MD, Moscow, Россия <i>with the support of the Lancet</i>
14.55-15.00	Questions
15.00-15.10	General discussion
	Closing of the first day of the conference
APRIL 27, 2025	
MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISORDER AND ALLO-HSCT APPROACHES PLENARY SESSION	
Hall 1	
Healthcare organization	
CHAIRMEN Amir Ali Hamidieh Elena Parovichnikova Fevzi Altuntaş Miralisher Islamov	
09.00-09.12	I - Healthcare organization: Iran Prof. Dr. Amir Ali Hamidieh, MD (Iran)
09.12-09.15	Discussion
09.15-09.27	R - Healthcare organization: Russia Dr. Elena Parovichnikova, MD (Russia)
09.27-09.30	Discussion
09.30-09.42	T - Healthcare organization: Türkiye Prof. Dr. Fevzi Altuntaş, MD (Türkiye)
09.42-09.45	Discussion
09.45-09.57	U - Healthcare organization: Uzbekistan Dr. Miralisher Islamov, MD (Uzbekistan)
09.57-10.00	Discussion
Life-threatening infections: KPE, invasive mycoses, viral infections	
CHAIRMEN Burcu Çalışkan Demirkiran Galina Klyasova Hamid Eshaghi Sardor Mukhammadiev	
15.15-15.27	Infections caused by carbapenemase-producing Enterobacteriales in hematological patients Prof. Dr. Galina Klyasova, MD (Russia)
15.27-15.30	Discussion
15.30-15.42	Fungal infections in routine practice in Türkiye Dr. Burcu Çalışkan Demirkiran, MD (Türkiye)
15.42-15.45	Discussion
15.45-15.57	CMV infection in children undergoing hematopoietic stem cell transplantation Dr. Hamid Eshaghi, MD (Iran)
15.57-16.00	Discussion
16.00-16.12	Infections in allo-HSCT patients in Uzbekistan Dr. Sardor Mukhammadiev, MD (Uzbekistan)
16.12-16.15	Discussion
MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES	
Hall 1	
Thalassemia/sickle cell anemia/AIHA	
CHAIRMEN Dilora Suleymanova Gennady Galstyan Hadi Mottaghipisheh Mehmet Bakırtaş Mehmut Bakir Koyuncu	
10.00-10.12	Immune thrombocytopenia Dr. Mehmet Bakırtaş, MD (Türkiye)
10.12-10.15	Discussion
10.15-10.27	Tailored treatment of immune thrombotic thrombocytopenic purpura Prof., Dr. Gennady Galstyan, MD (Russia)
10.27-10.30	Discussion
10.30-10.42	Anemia and thalassemia in Uzbekistan Prof., Dr. Dilora Suleymanova, MD (Uzbekistan)
10.42-10.45	Discussion
10.45-10.57	Approach to the treatment of thalassemias in Türkiye Dr. Mahmut Bakir Koyuncu, MD (Türkiye)
10.57-11.00	Discussion
11.00-11.12	Modern approaches to the treatment of sickle cell anemia: from gene therapy to modern drugs Dr. Hadi Mottaghipisheh, MD (Iran)
11.12-11.15	Discussion
Acute leukemia/MDS	
CHAIRMEN Elena Parovichnikova Sayeh Parkhideh Eldor Iskhakov Rafiye Çiftçiler Aziz Eghbali	
11.15-11.27	Clinical trials in patients with acute leukemia in Russia Dr. Elena Parovichnikova, MD (Russia)
11.27-11.30	Discussion
11.30-11.42	Update treatment of MDS Dr. Sayeh Parkhideh, MD (Iran)
11.42-11.45	Discussion
11.45-11.57	Treatment of AML with modern drugs: own experience Dr. Rafiye Çiftçiler, MD (Türkiye)
11.57-12.00	Discussion
12.00-12.12	Immunotherapy in pediatric acute lymphoblastic leukemia: recent advances and future perspectives Dr. Aziz Eghbali, MD (Iran)
12.12-12.15	Discussion
12.15-12.27	Acute leukemia and pregnancy. A rare condition with rare disease Dr. Eldor Iskhakov, MD (Uzbekistan)
12.27-12.30	Discussion
Multiple myeloma	
CHAIRMEN Bahar Uncu Ulu Larisa Mendeleeva Farzaneh Ashrafi Maxim Solovov Gulchehra Mahammadalieva	
12.30-12.42	Monoclonal Gammopathies: More Than Just a Lab Result Dr. Farzaneh Ashrafi, MD (Iran)
12.42-12.45	Discussion
12.45-12.57	Primary plasma cell leukemia: diagnosis and treatment Dr. Maxim Solovov, MD (Russia)
12.57-13.00	Discussion
13.00-13.12	New approaches to the treatment of multiple myeloma Dr. Gulchexra Mahamadaliyeva, MD (Uzbekistan)
13.12-13.15	Discussion
13.15-13.27	Clinical trials in Türkiye Dr. Bahar Uncu Ulu, MD (Türkiye)
13.27-13.30	Discussion
Hodgkin's lymphoma/NHL/CLL	
CHAIRMEN Evgeny Zvonkov Düzgün Özatlı Nelly Gabeeva Maryam Barkhordar Kamoliddin Olimjonov	
13.30-13.42	Follicular lymphoma. One mask - many faces Dr. Nelly Gabeeva, MD (Russia)
13.42-13.45	Discussion
13.45-13.57	Approaches to the treatment of DLBC lymphoma Dr. Düzgün Özatlı, MD (Türkiye)
13.57-14.00	Discussion
14.00-14.12	Immune cell therapy for lymphoma Dr. Maryam Barkhordar, MD (Iran)
14.12-14.15	Discussion
14.15-14.27	Auto-HSCT for lymphoma patients Dr. Kamoliddin Olimjonov, MD (Uzbekistan)
14.27-14.30	Discussion
CML - algorithms for managing CML patients in different countries	
CHAIRMEN Anna Turkina Mehmet Sinan Dal Ekaterina Chelysheva Hossein Ghasemi Moghaddam	
14.30-14.42	Algorithms for managing patients with CML in Türkiye Prof. Dr. Mehmet Sinan Dal, MD (Türkiye)
14.42-14.45	Discussion
14.45-14.57	Treatment options for CML with an optimal response Dr. Ekaterina Chelysheva, MD (Russia)
14.57-15.00	Discussion
15.00-15.12	Advanced phase CML Dr. Hossein Ghasemi Moghaddam, MD (Iran)
15.00-15.15	Discussion
Hemophilia: today and tomorrow	
CHAIRMEN Aziza Makhmudova Cengiz Demir MD Nadezhda Zozulya Babak Abdolkarimi	
16.15-16.27	Hemophilia treatment in Russia Dr. Nadezhda Zozulya, MD (Russia)
16.27-16.30	Discussion
16.30-16.42	Hemophilia treatment Prof., Dr. Cengiz Demir, MD (Türkiye)
16.42-16.45	Discussion
16.45-16.57	Novel treatment approach in hemophilia Dr. Babak Abdolkarimi, MD (Iran)
16.57-17.00	Discussion
17.00-17.12	Approaches to the treatment of hemophilia in Uzbekistan Prof., Dr. Aziza Makhmudova, MD (Uzbekistan)
17.12-17.15	Discussion
APPROACHES TO TRANSPLANTATION	
Hall 2	
Allo-HSCT in hematological malignancies	
CHAIRMEN Abdurakhman Kayumov Fevzi Altuntaş Abbas Hajifathali Mikhail Drovkov	
10.00-10.12	Conditions and prospects for the development of HSCT in Uzbekistan Dr. Abdurakhman Kayumov, MD (Uzbekistan)
10.12-10.15	Discussion
10.15-10.27	The structure of adult allo-HSCT care in Russia Dr. Mikhail Drovkov, MD (Russia)
10.27-10.30	Discussion
10.30-10.42	Hematopoietic stem cell transplantation activity in Türkiye Prof., Dr. Fevzi Altuntaş, MD (Türkiye)
10.42-10.45	Discussion
10.45-10.57	T-cell depletion in allogeneic hematopoietic stem cell transplant Dr. Abbas Hajifathali, MD (Iran)
10.57-11.00	Discussion
Aplastic anemia/ bone marrow failure syndromes and transplantation in non-malignant diseases	
CHAIRMEN Amir Ali Hamidieh Elena Mikhailova Mehmet Bakırtas Zahida Falahati Valina Fidarova Inna Berger	
11.00-11.12	Allogeneic hematopoietic stem cell transplantation for Inherited bone marrow failure Prof. Dr. Amir Ali Hamidieh, MD (Iran)
11.12-11.15	Discussion
11.15-11.27	Impaired supportive function of the stromal environment in bone marrow in aplastic anemia Dr. Inna Berger, MD (Uzbekistan)
11.27-11.30	Discussion
11.30-11.42	Halpidentical hematopoietic stem cell transplantation for severe acquired aplastic anemia Dr. Vahid Falahati, MD (Iran)
11.42-11.45	Discussion
11.45-11.57	Haplo-HSCT in the first line treatment for aplastic anemia with severe infections Dr. Zalina Fidarova, MD (Russia)
11.57-12.00	Discussion
GVHD prophylaxis/Graft failure	
CHAIRMEN Maryam Behfar Burhan Turgut Ozoda Achilova Natalia Popova Mikhail Drovkov	
12.15-12.27	GVHD prophylaxis approach in allo-HSCT in Türkiye Dr. Burhan Turgut, MD (Türkiye)
12.27-12.30	Discussion
12.30-12.42	Results of low-doses PT-Cy in the prevention of GVHD in after allo-HSCT in Uzbekistan Dr. Ozoda Achilova, MD (Uzbekistan)
12.42-12.45	Discussion
12.45-12.57	The impact of anti-HLA antibodies on graft failure in HSCT Dr. Maryam Behfar, MD (Iran)
12.57-13.00	Discussion
13.00-13.12	Graft failure: Challenges in definition. Single-center experience Dr. Natalia Popova, MD (Russia)
13.12-13.15	Discussion
Acute GVHD/Chronic GVHD	
CHAIRMEN Mikhail Drovkov Mahmut Yeral Leyla Jafari Vera Vasilyeva Saidburkhon Asilov	
13.15-13.27	Structure of acute and chronic GVHD in Uzbekistan Dr. Saidbukhon Asilov, MD (Uzbekistan)
13.27-13.30	Discussion
13.30-13.42	Approaches to the treatment of SR-GVHD: ruxolitinib vs ECP Prof. Dr. Mahmut Yeral, MD (Türkiye)
13.42-13.45	Discussion
13.45-13.57	Cryopreservation as an alternative approach for applying photopheresis products to treat GVHD among pediatric patients Dr. Leyla Jafari, MD (Iran)
13.57-14.00	Discussion
14.00-14.12	Therapy for steroid-refractory acute and chronic graft-versus-host disease using cryopreserved mononuclear cells subjected to extracorporeal phototherapy Dr. Vera Vasilyeva, MD (Russia)
14.12-14.15	Discussion
Intensive care for allo-HSCT	
CHAIRMEN Gennady Galstyan Zeinab Najafi Ilhami Berber Dano Julamanova Antonina Shchekina	
14.15-14.27	Outcomes in critically ill allogeneic hematopoietic stem cell transplantation recipients Dr. Antonina Shchekina, MD (Russia)
14.27-14.30	Discussion
14.30-14.42	Thrombotic microangiopathy after HSCT Prof. Dr. Ilhami Berber, MD (Türkiye)
14.42-14.45	Discussion
14.45-14.57	Critical care pulmonary issues after HSCT Dr. Zeinab Najafi, MD (Iran)
14.57-15.00	Discussion
15.00-15.12	Intensive care in Uzbekistan Dr. Dano Julamanova, MD (Uzbekistan)
15.12-15.15	Discussion
Cell therapy	
CHAIRMEN Abdurakhman Kayumov Hamid Farajifard Samet Yaman Olga Aleshina Farkhodjon Tashtemirov	
16.15-16.27	CAR-T therapy: evolving art of ALL treatment Dr. Olga Aleshina, MD (Russia)
16.27-16.30	Discussion
16.30-16.42	CAR-T cells and cell therapy in Türkiye Dr. Samet Yaman, MD (Türkiye)
16.42-16.45	Discussion
16.45-16.57	Adaptive T-cell therapy in CMV infection Dr. Hamid Farajifard, MD (Iran)
16.57-17.00	Discussion
17.00-17.12	Cell therapy needs and legislation in Uzbekistan Dr. Farkhodjon Tashtemirov, MD (Uzbekistan)
17.12-17.15	Discussion
SPONSORS	

